文献速递消化与肝胆胰病理细胞病理与分子病理

p53免疫组化在Barrett食管诊断中的影响与可重复性:荷兰食管病理专家组研究

Diagnostic impact and reproducibility of p53 immunohistochemistry in Barrett's oesophagus: results of the Dutch Esophageal Pathology Panel (DEPP).
PubMed 文献 · Histopathology · 2026-06-19

该研究基于荷兰全国真实世界Barrett食管队列,评估p53免疫组化与转诊医院的一致性、观察者间一致性及其对常规诊断决策的影响。结果显示p53评估一致性中等至较好,24.2%的p53评估被重新分类,标准化标准下p53免疫组化可靠且具有临床意义。

要点

  • p53免疫组化与转诊医院一致性中等至较好(κ=0.61)。
  • 专家组间观察者一致性较好(κ=0.65),24.2%的p53评估被重新分类。
  • p53免疫组化可影响活检级别的诊断决策,支持常规应用。

核心结论

  • 在标准化标准下,p53免疫组化解读在Barrett食管诊断中可靠、可重复且具有临床意义。
  • 研究结果支持在常规实践中更广泛地使用p53免疫组化,并将评估标准纳入指南。

研究设计与样本

  • 研究评估了提交至荷兰食管病理专家组(DEPP)的连续会诊病例,由经过培训且经验丰富的病理学家进行H&E分类(维也纳分类)、p53免疫组化模式评估及H&E/p53免疫组化联合审阅。
  • 共纳入1,146例连续患者会诊病例(1,704个活检级别),每例活检中位DEPP病理学家评估次数为12次。
  • 评估了转诊医院与专家组的p53评估一致性(Cohen's kappa)及13名病理学家对316例内镜活检的观察者间一致性(Fleiss' kappa),并分析p53免疫组化对诊断重新分类的影响。

主要发现

  • 转诊医院与专家组p53评估总体一致性为中等至较好(κ=0.61,95% CI 0.58-0.64),24.2%的p53免疫组化评估被重新分类。
  • 13名病理学家评估316例内镜活检的观察者间一致性为较好(κ=0.65,95% CI 0.61-0.69)。
  • 对于非异型增生(NDBE)活检,异常p53免疫组化促使重新分类为不确定异型增生(IND,9.2%)或低级别异型增生(LGD,4.8%)。
  • 对于IND活检,p53免疫组化使诊断转向NDBE(17.0%)或LGD(37.1%)。
  • 辅助p53免疫组化在各活检级别影响病理学家的决策。

关键数值与推荐

  • p53免疫组化模式包括野生型、过表达、双克隆、缺失突变和不确定型。
  • H&E分类采用维也纳分类。
  • 转诊医院与专家组p53评估一致性κ=0.61(95% CI 0.58-0.64)。
  • 观察者间一致性κ=0.65(95% CI 0.61-0.69)。
  • p53免疫组化重新分类比例:NDBE→IND 9.2%,NDBE→LGD 4.8%,IND→NDBE 17.0%,IND→LGD 37.1%。

临床怎么用

  • 在Barrett食管诊断中,应采用标准化标准解读p53免疫组化,以提高诊断一致性和可重复性。
  • p53免疫组化可辅助H&E分类,影响非异型增生和不确定异型增生活检的诊断决策。
  • 建议将p53免疫组化评估标准纳入指南,以支持其在常规实践中的更广泛应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Evidence supporting the use of p53 immunohistochemistry (p53-IHC) in Barrett's oesophagus (BE) is largely based on selected series, limiting generalizability. This study evaluates p53-IHC in a nationwide, real-world BE-cohort within a universal healthcare system, assessing concordance with referring hospitals, interobserver agreement (IOA) and its impact on routine diagnostic decisions. METHODS: Revision cases submitted to the Dutch Esophageal Pathology Panel (DEPP) were assessed by trained and experienced pathologists for haematoxylin and eosin (H&E)-based classification (Vienna classification), p53-IHC patterns (wild-type, overexpression, double clone, null mutation and equivocal) and combined H&E/p53-IHC review. Concordance between referring hospitals and the expert panel (Cohen's kappa) and IOA among panel pathologists (Fleiss' kappa) were assessed, along with the impact of p53-IHC on diagnostic reclassification. RESULTS: A total of 1,146 consecutive patient consultation cases (1,704 biopsy levels) were included, with a median of 12 DEPP pathologist assessments per biopsy. Overall concordance of p53 assessment between referring hospitals and the expert panel was moderate-to-substantial (κ = 0.61, 95% CI 0.58-0.64), with 24.2% of p53-IHC assessments reclassified. IOA among 13 pathologists assessing 316 endoscopic biopsies was substantial (κ = 0.65, 95% CI 0.61-0.69). Ancillary p53-IHC influenced pathologists' decisions across biopsy levels. For non-dysplastic (NDBE) biopsies, aberrant p53-IHC prompted reclassification to indefinite for dysplasia (IND, 9.2%) or low-grade dysplasia (LGD, 4.8%). For IND biopsies, p53-IHC shifted diagnoses toward NDBE (17.0%) or LGD (37.1%). CONCLUSION/DISCUSSION: p53-IHC interpretation is reliable, reproducible and clinically meaningful in BE diagnostics when standardized criteria are applied. These findings support broader use of p53-IHC in routine practice and incorporation of assessment criteria into guidelines.

来源:Histopathology,查看原文。版权归原作者所有。

引用

  1. Weeda YA, Issa SM, Halfwerk H, et al. Diagnostic impact and reproducibility of p53 immunohistochemistry in Barrett's oesophagus: results of the Dutch Esophageal Pathology Panel (DEPP). Histopathology. 2026. PMID: 42318944. doi:10.1111/his.70193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。